Compare TUSK & INO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TUSK | INO |
|---|---|---|
| Founded | 2014 | 1979 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Medical/Dental Instruments |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 137.3M | 118.9M |
| IPO Year | 2016 | 1999 |
| Metric | TUSK | INO |
|---|---|---|
| Price | $3.16 | $1.25 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $6.75 |
| AVG Volume (30 Days) | 102.0K | ★ 3.2M |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 102.32 | 54.18 |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $44,292,000.00 | $42,220,086.00 |
| Revenue This Year | $383.90 | $20,156.19 |
| Revenue Next Year | N/A | $421.95 |
| P/E Ratio | $35.78 | ★ N/A |
| Revenue Growth | N/A | ★ 19.37 |
| 52 Week Low | $1.72 | $0.56 |
| 52 Week High | $3.92 | $2.72 |
| Indicator | TUSK | INO |
|---|---|---|
| Relative Strength Index (RSI) | 54.05 | 53.35 |
| Support Level | $2.98 | $1.22 |
| Resistance Level | $3.32 | $1.24 |
| Average True Range (ATR) | 0.12 | 0.09 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 65.67 | 43.24 |
Mammoth Energy Services Inc is an integrated energy services company engaged in providing products and services to enable the exploration and development of North American onshore unconventional oil and natural gas reserves as well as the construction and repair of the electric grid for private utilities, public investor-owned utilities, and co-operative utilities through infrastructure services businesses. The company had three reportable segments, which includes rental services, infrastructure services, natural sand proppant services, accommodation services, and drilling services.
Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.